Focus Rheums| ACR Convergence 2024 Previews

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

Sex Differences & Rheumatoid Arthritis

Tuulikki Sokka, MD, PhD  |  Issue: December 2009  |  

Considering these factors, language used to describe outcomes in rheumatic disease may need modification as well as a new conceptualization. Thus, the phrase “Male sex—a major predictor of remission” might be more accurately stated as “Male sex—a major predictor of meeting remission criteria.”49 Furthermore, in trying to convey better male–female differences in the course of RA, it is important to consider that disease-activity measures, especially in the setting of low disease activity near remission, behave differently in men than in women; there are nevertheless exceptions.50

Therefore, one may pose the question of whether we need new criteria for remission that treat men and women separately. Certainly, the current criteria sets used for RA remission vary in stringency, thereby affecting the percentage of patients achieving a level of disease activity operationally defined as remission. Among the criteria sets, the level of activity defining remission may vary depending on the number of factors assessed, the weighting, and even the number of joints assessed. Therefore, in populations of patients, remission rates have to be interpreted in light of the definition that has been used for remission. In case of an individual patient, however, whether a man or a woman, “we recognize it (remission) when we see it,” according to a wise suggestion by Paulus.51

ADVERTISEMENT
SCROLL TO CONTINUE

Data and beliefs exert powerful influences on science and medicine and affect the way we think and the way we act. Rheumatology is no different than other specialties, although, when it comes to the matter of sex, beliefs may have trumped data. From my reading of the data, I would conclude that, despite some differences in the measures of disease activity, RA is essentially the same disease in women and men. Furthermore, anyone who has read this article to this point may conclude that news concerning differences in disease course between women and men, like everything else having to do with sex, can attract attention. Now that I have your attention, I hope that you will look at the data.

Acknowledgement: This article is based in part on data presented in Sokka T, et al. Arthritis Res Ther. 2009; 11(1):R7.

ADVERTISEMENT
SCROLL TO CONTINUE

Dr. Sokka is a rheumatologist at the Jyväskylä Central Hospital in Jyväskylä, Finland.

References

  1. Weyand CM, Schmidt D, Wagner U, Goronzy JJ. The influence of sex on the phenotype of rheumatoid arthritis. Arthritis Rheum. 1998;41:817-822.
  2. Boers M. Does sex of the rheumatoid arthritis patients matter? Lancet. 1998;352:419-420
  3. Forslind K, Hafstrom I, Ahlmen M, Svensson B. Sex: A major predictor of remission in early rheumatoid arthritis? Ann Rheum Dis. 2007;66:46-52.
  4. Mancarella L, Bobbio-Pallavicini F, Ceccarelli F, et al. Good clinical response, remission, and predictors of remission in rheumatoid arthritis patients treated with tumor necrosis factor-alpha blockers: The GISEA study. J Rheumatol. 2007;34:1670-1673.
  5. Hyrich KL, Watson KD, Silman AJ, Symmons DP, British Society for Rheumatology Biologics Register. Predictors of response to anti-TNF-a therapy among patients with rheumatoid arthritis: Results from the British Society for Rheumatology Biologics Register. Rheumatology (Oxford). 2006;45:1558-1565.
  6. Yamanaka H, Tanaka Y, Sekiguchi N, et al. Retrospective clinical study on the notable efficacy and related factors of infliximab therapy in a rheumatoid arthritis management group in Japan (RECONFIRM). Mod Rheumatol. 2007;17:28-32.
  7. Kvien TK, Uhlig T, Odegard S, Heiberg MS. Epidemiological aspects of rheumatoid arthritis: The sex ratio. Ann N Y Acad Sci. 2006;1069:212-222.
  8. Burmester GR, Mariette X, Montecucco C, et al. Adalimumab alone and in combination with disease-modifying antirheumatic drugs for the treatment of rheumatoid arthritis in clinical practice: The Research in Active Rheumatoid Arthritis (ReAct) trial. Ann Rheum Dis. 2007;66:732-739.
  9. Takeuchi T, Tatsuki Y, Nogami Y, et al. Postmarketing surveillance of the safety profile of infliximab in 5,000 Japanese patients with rheumatoid arthritis. Ann Rheum Dis. 2008;67:189-194.
  10. Jawaheer D, Lum RF, Gregersen PK, Criswell LA. Influence of male sex on disease phenotype in familial rheumatoid arthritis. Arthritis Rheum. 2006;54:3087-3094.
  11. Straub RH, Harle P, Sarzi-Puttini P, Cutolo M. Tumor necrosis factor-neutralizing therapies improve altered hormone axes: An alternative mode of antiinflammatory action. Arthritis Rheum. 2006;54:2039-2046.
  12. Krishnan E, Sokka T, Hannonen P. Smoking-gender interaction and risk for rheumatoid arthritis. Arthritis Res Ther. 2003;5:R158-R162.
  13. Jantti JK, Kaarela K, Belt EA, Kautiainen HJ. Incidence of severe outcome in rheumatoid arthritis during 20 years. J Rheumatol. 2002;29:688-692.
  14. Yelin E, Meenan R, Nevitt M, Epstein W. Work disability in rheumatoid arthritis: Effects of disease, social, and work factors. Ann Intern Med. 1980;93:551-556.
  15. Mäkisara GL, Mäkisara P. Prognosis of functional capacity and work capacity in rheumatoid arthritis. Clin Rheumatol. 1982;1:117-125.
  16. Scott DL, Grindulis KA, Struthers GR, et al. Progression of radiological changes in rheumatoid arthritis. Ann Rheum Dis. 1984;43:8-17.
  17. Pincus T, Callahan LF, Sale WG, et al. Severe functional declines, work disability, and increased mortality in seventy-five rheumatoid arthritis patients studied over nine years. Arthritis Rheum. 1984;27:864-872.
  18. Kaarela K. Prognostic factors and diagnostic criteria in early rheumatoid arthritis. Scand J Rheumatol Suppl. 1985;57:1-54.
  19. Sokka T, Kautiainen H, Toloza S, et al. QUEST-RA: quantitative clinical assessment of patients with rheumatoid arthritis seen in standard rheumatology care in 15 countries. Ann Rheum Dis. 2007;66:1491-1496.
  20. Bergstrom U, Book C, Lindroth Y, et al. Lower disease activity and disability in Swedish patients with rheumatoid arthritis in 1995 compared with 1978. Scand J Rheumatol. 1999;28:160-165.
  21. Pincus T, Sokka T, Kautiainen H. Patients seen for standard rheumatoid arthritis care have significantly better articular, radiographic, laboratory, and functional status in 2000 than in 1985. Arthritis Rheum. 2005;52:1009-1019.
  22. Sokka T, Möttönen T, Hannonen P. Disease-modifying anti-rheumatic drug use according to the “sawtooth” treatment strategy improves the functional outcome in rheumatoid arthritis: Results of a long-term follow-up study with review of the literature. Rheumatology. 2000;39:34-42.
  23. Krishnan E, Fries JF. Reduction in long-term functional disability in rheumatoid arthritis from 1977 to 1998: A longitudinal study of 3035 patients. Am J Med. 2003;115:371-376.
  24. Heiberg T, Finset A, Uhlig T, Kvien TK. Seven year changes in health status and priorities for improvement of health in patients with rheumatoid arthritis. Ann Rheum Dis. 2005; 64:191-195.
  25. Sokka TM, Kaarela K, Möttönen TT, Hannonen PJ. Conventional monotherapy compared to a “sawtooth” treatment strategy in the radiographic procession of rheumatoid arthritis over the first eight years. Clin Exp Rheumatol. 1999;17:527-532.
  26. Sokka T, Kautiainen H, Häkkinen K, Hannonen P. Radiographic progression is getting milder in patients with early rheumatoid arthritis. Results of 3 cohorts over 5 years. J Rheumatol. 2004;31:1073-1082.
  27. Sokka T, Kautiainen H, Hannonen P. Stable occurrence of knee and hip total joint replacement in Central Finland between 1986 and 2003: An indication of improved long-term outcomes of rheumatoid arthritis. Ann Rheum Dis. 2007;66:341-344.
  28. 28. Puolakka K, Kautiainen H, Möttönen T, et al. Early suppression of disease activity is essential for maintenance of work capacity in patients with recent-onset rheumatoid arthritis: Five-year experience from the FIN-RACo trial. Arthritis Rheum. 2005;52:36-41.
  29. Krause D, Schleusser B, Herborn G, Rau R. Response to methotrexate treatment is associated with reduced mortality in patients with severe rheumatoid arthritis. Arthritis Rheum. 2000;43:14-21.
  30. Choi HK, Hernán MA, Seeger JD, Robins JM, Wolfe F. Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study. Lancet. 2002;359:1173-1177.
  31. Isomäki HA. Mortality in Patients with Rheumatoid Arthritis. In: Wolfe F, Pincus T, eds. Rheumatoid Arthritis: Pathogenesis, Assessment, Outcome, and Treatment. New York: Marcel Dekker, Inc.; 1994:235-246.
  32. Sokka T, Toloza S, Cutolo M, et al. Women, men, and rheumatoid arthritis: Analyses of disease activity, disease characteristics, and treatments in the QUEST-RA Study. Arthritis Res Ther. 2009;11(1):R7.
  33. Leeb BF, Haindl PM, Maktari A, Nothnagl T, Rintelen B. Disease activity score-28 values differ considerably depending on patient’s pain perception and sex. J Rheumatol. 2007; 34:2382-2387.
  34. Sokka T, Kautiainen H, Pincus T, et al. Disparities in rheumatoid arthritis disease activity according to gross domestic product in 25 countries in the QUEST-RA database. Ann Rheum Dis. 2009 July 31 (Epub ahead of print).
  35. Sokka T, Hetland ML, Makinen H, et al. Remission and rheumatoid arthritis: Data on patients receiving usual care in twenty-four countries. Arthritis Rheum. 2008;58:2642-2651.
  36. Luukkainen R, Kaarela K, Isomäki H, et al. The prediction of radiological destruction during the early stage of rheumatoid arthritis. Clin Exp Rheumatol. 1983;1:295-298.
  37. Ahlmen M, Svensson B, Albertsson K, Forslind K, Hafstrom I. Influence of gender on assessments of disease activity and function in early rheumatoid arthritis in relation to radiographic joint damage. Ann Rheum Dis. 2009 Jan 21 (Epub ahead of print).
  38. Gossec L, Baro-Riba J, Bozonnat MC, et al. Influence of sex on disease severity in patients with rheumatoid arthritis. J Rheumatol. 2005;32:1448-1451.
  39. Sokka T, Makinen H, Hannonen P, Pincus T. Most people over age 50 in the general population do not meet ACR remission criteria or OMERACT minimal disease activity criteria for rheumatoid arthritis. Rheumatology (Oxford). 2007;46:1020-1023.
  40. Katz PP, Criswell LA. Differences in symptom reports between men and women with rheumatoid arthritis. Arthritis Care Res. 1996;9:441-448.
  41. Sherrer YS, Bloch DA, Mitchell DM, et al. Disability in rheumatoid arthritis: Comparison of prognostic factors across three populations. J Rheumatol. 1987;14:705-709.
  42. Puolakka K, Kautiainen H, Pekurinen M, et al. Monetary value of lost productivity over a 5-year follow up in early rheumatoid arthritis estimated on the basis of official register data on patients’ sickness absence and gross income: Experience from the FIN-RACo Trial. Ann Rheum Dis. 2006;65:899-904.
  43. Thompson PW, Pegley FS. A comparison of disability measured by the Stanford Health Assessment Questionnaire disability scales (HAQ) in male and female rheumatoid outpatients. Br J Rheumatol. 1991;30:298-300.
  44. McKenna F, Tracey A, Hayes J. Assessment of disability in male and female rheumatoid patients. Br J Rheumatol. 1991;30:477.
  45. Sokka T, Krishnan E, Häkkinen A, Hannonen P. Functional disability in rheumatoid arthritis patients compared with a community population in Finland. Arthritis Rheum. 2003; 48:59-63.
  46. Krishnan E, Sokka T, Hakkinen A, Hubert H, Hannonen P. Normative values for the Health Assessment Questionnaire disability index: Benchmarking disability in the general population. Arthritis Rheum. 2004;50:953-960.
  47. Hakkinen A, Kautiainen H, Hannonen P, et al. Muscle strength, pain, and disease activity explain individual subdimensions of the health assessment questionnaire disability index, especially in women with rheumatoid arthritis. Ann Rheum Dis. 2006;65:30-34.
  48. Hallert E, Thyberg I, Hass U, Skargren E, Skogh T. Comparison between women and men with recent onset rheumatoid arthritis of disease activity and functional disability over two years (the TIRA project). Ann Rheum Dis. 2003;62:667-670.
  49. Makinen H, Hannonen P, Sokka T. Sex: A major predictor of remission as measured by 28-joint Disease Activity Score (DAS28) in early rheumatoid arthritis? Ann Rheum Dis. 2008;67:1052-1053.
  50. Radovits BJ, Fransen J, van Riel PL, Laan RF. Influence of age and gender on the Disease Activity Score-28 (DAS28) in rheumatoid arthritis. Ann Rheum Dis. 2008;67:1127-1131.
  51. Paulus HE. Defining remission in rheumatoid arthritis: What is it? Does it matter? J Rheumatol. 2004;31:1-4.

Related Articles